Literature DB >> 31411993

Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer.

Umberto Capitanio1, Alessandro Larcher2, Francesco Cianflone3, Francesco Trevisani3, Alessandro Nini3, Alexandre Mottrie4, Andrea Mari5, Riccardo Campi5, Riccardo Tellini6, Alberto Briganti3, Alessandro Veccia6, Hendrik Van Poppel7, Marco Carini5, Claudio Simeone6, Andrea Salonia3, Andrea Minervini5, Alessandro Antonelli6, Francesco Montorsi3, Roberto Bertini3.   

Abstract

BACKGROUND: Despite better renal function following nephron-sparing surgery (NSS) relative to radical nephrectomy (RN), there is no consensus with respect to the long-term sequelae associated with surgery.
OBJECTIVE: To investigate the effect of surgery and the temporal pattern of two different cardiovascular event (CVe) categories after NSS versus RN. DESIGN, SETTING, AND PARTICIPANTS: We collected data of 898 patients with cT1-2 N0 M0 renal mass and no history of CVe treated with NSS versus RN. CVe categories were dichotomised in (1) de novo hypertension (HT) and (2) other major cardiovascular events (MCEs). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable competing regression analyses (MVAs) tested the adjusted effect of surgery type on each CVe category. RESULTS AND LIMITATIONS: Among patients treated with RN, 38% of HT events occurred immediately after surgery. Conversely, in NSS counterparts, the onset of HT was diluted over the years after surgery (10% of HT events in the first 6 mo). When an MCE was considered, an increasing long-term time-dependent prevalence of the outcome was observed in both groups, with no statistically significantly difference between NSS and RN. At MVA, RN was associated with a higher HT risk (hazard ratio [HR] 2.89; p=0.006) than but a similar MCE risk (HR 0.85; p=0.6) to NSS.
CONCLUSIONS: Relative to RN, NSS showed an independent protective effect on HT but not on MCEs. In patients with no history of preoperative HT or MCEs, the onset of HT after RN is a very early event, due probably to the acute loss of renal parenchyma. This is not the case for the other cardiovascular morbidity, which develops in the long-term period, regardless of the type of surgery performed. PATIENT
SUMMARY: In renal cancer patients without a medical history of cardiopathy, preserving healthy kidney tissue at surgery is associated with a decreased risk of developing postoperative hypertension.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiovascular events; Hypertension; Kidney cancer; Partial nephrectomy; Radical nephrectomy; Renal cancer

Year:  2019        PMID: 31411993     DOI: 10.1016/j.euo.2019.02.006

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  12 in total

1.  [New aspects in the treatment of localized renal cell carcinoma].

Authors:  P Zeuschner; S Siemer
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

2.  The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery.

Authors:  Giuseppe Rosiello; Alessandro Larcher; Giuseppe Fallara; Giuseppe Basile; Daniele Cignoli; Gianmarco Colandrea; Chiara Re; Francesco Trevisani; Pierre I Karakiewicz; Andrea Salonia; Roberto Bertini; Alberto Briganti; Francesco Montorsi; Umberto Capitanio
Journal:  World J Urol       Date:  2020-10-29       Impact factor: 4.226

3.  Competing risk analysis of cardiovascular/cerebrovascular death in T1/2 kidney cancer: a SEER database analysis.

Authors:  Xiaofei Mo; Mingge Zhou; Hui Yan; Xueqin Chen; Yuetao Wang
Journal:  BMC Cancer       Date:  2021-01-05       Impact factor: 4.430

4.  Global Analysis of Research Trends on Kidney Function After Nephron-Sparing Surgery: A Bibliometric and Visualised Study.

Authors:  Faris Abushamma; Abdulkarim Barqawi; Samah W Al-Jabi; Maha Akkawi; Mosab Maree; Sa'ed H Zyoud
Journal:  Cancer Manag Res       Date:  2021-09-27       Impact factor: 3.989

Review 5.  Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.

Authors:  Francesco Trevisani; Matteo Floris; Roberto Minnei; Alessandra Cinque
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

6.  Assessment of Stiffness of Large to Small Arteries in Multistage Renal Disease Model: A Numerical Study.

Authors:  Hasan Obeid; Vasiliki Bikia; Catherine Fortier; Mathilde Paré; Patrick Segers; Nikos Stergiopulos; Mohsen Agharazii
Journal:  Front Physiol       Date:  2022-03-30       Impact factor: 4.566

7.  Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management.

Authors:  Jordana B Cohen; Abdallah S Geara; Jonathan J Hogan; Raymond R Townsend
Journal:  JACC CardioOncol       Date:  2019-12-17

8.  Zero ischemia laparoscopic microwave ablation assisted enucleation vs. laparoscopic partial nephrectomy in clinical T1a renal tumor: a randomized clinical trial.

Authors:  Xiaorong Wu; Wei Chen; Jiwei Huang; Jin Zhang; Dongming Liu; Yiran Huang; Yonghui Chen; Wei Xue
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

9.  Functional, oncological outcomes and safety of nephron-sparing surgery versus radical nephrectomy in patients with localised renal cell carcinoma with high anatomical complexity: a retrospective cohort study with propensity score matching method.

Authors:  Xuanyu Zhang; Zhonghua Su; Peng Lv; Zeqi Liu; Song Bai
Journal:  BMJ Open       Date:  2021-12-24       Impact factor: 2.692

10.  Cystatin C predicts renal function impairment after partial or radical tumor nephrectomy.

Authors:  Mike Wenzel; Hang Yu; Annemarie Uhlig; Christoph Würnschimmel; Manuel Wallbach; Andreas Becker; Margit Fisch; Felix K H Chun; Christian P Meyer; Marianne Leitsmann
Journal:  Int Urol Nephrol       Date:  2021-07-16       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.